The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Sign in to access this content
Sign InAmid a broader trend of institutional managers repositioning portfolios ahead of shifting market dynamics, Capital International has disclosed significant adjustments to its core holdings. Capital International Investors nearly doubled its stake in Johnson & Johnson, increasing its position by 93.3% to a total value of $1.55 billion, while Capital International Sarl boosted its L3Harris Technologies investment by 39.3%. Conversely, Capital International Inc. CA reduced its exposure to Wells Fargo by 28.9% and trimmed its Gilead Sciences holdings by 9.7% during the fourth quarter.
These shifts occur as the banking sector faces mixed sentiment, with Wells Fargo navigating competition from peers like JPMorgan Chase, which closed at $312.37, and Bank of America at $53.83 per market data. The aggressive pivot toward Johnson & Johnson reflects a rotation into defensive healthcare assets, following the company's robust Q1 earnings performance which surpassed consensus estimates (per historical earnings reports).
Traders should monitor price action around current levels, with JNJ closing at $232.77 and WFC at $81.94 as of the June 5, 2026 close. Looking ahead, institutional sentiment may be further influenced by upcoming central bank commentary, including scheduled speeches from Federal Reserve officials that could impact the valuation of large-cap dividend stocks in the coming days.